225 related articles for article (PubMed ID: 26526504)
1. Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
Ceresoli GL; Zucali PA
Cancer Treat Rev; 2015 Dec; 41(10):853-8. PubMed ID: 26526504
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Ceresoli GL; Garassino I; De Vincenzo F; Cavina R; Campagnoli E; Cappuzzo F; Salamina S; Soto Parra HJ; Santoro A
Cancer; 2008 Apr; 112(7):1555-61. PubMed ID: 18286536
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
Zauderer MG; Kass SL; Woo K; Sima CS; Ginsberg MS; Krug LM
Lung Cancer; 2014 Jun; 84(3):271-4. PubMed ID: 24690410
[TBL] [Abstract][Full Text] [Related]
5. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
[TBL] [Abstract][Full Text] [Related]
6. High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
Zimling ZG; Santoni-Rugiu E; Bech C; Sørensen JB
Anticancer Res; 2015 Dec; 35(12):6731-8. PubMed ID: 26637889
[TBL] [Abstract][Full Text] [Related]
7. Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
Agatsuma T; Koizumi T; Yasuo M; Urushihata K; Tsushima K; Yamamoto H; Hanaoka M; Fukushima M; Honda T; Kubo K
Jpn J Clin Oncol; 2010 Dec; 40(12):1180-3. PubMed ID: 20603247
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
[TBL] [Abstract][Full Text] [Related]
9. An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review.
Zilembo N; Vitali M; Pietrantonio F; Platania M; Del Vecchio M; Bajetta E
Tumori; 2010; 96(6):1031-4. PubMed ID: 21388071
[TBL] [Abstract][Full Text] [Related]
10. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
Pasello G; Nicotra S; Marulli G; Rea F; Bonanno L; Carli P; Magro C; Jirillo A; Favaretto A
Lung Cancer; 2011 Sep; 73(3):351-5. PubMed ID: 21296448
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.
Ak G; Metintas S; Akarsu M; Metintas M
BMC Cancer; 2015 Jul; 15():510. PubMed ID: 26156324
[TBL] [Abstract][Full Text] [Related]
12. Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
de Lima VA; Sørensen JB
Med Oncol; 2015 Feb; 32(2):458. PubMed ID: 25572813
[TBL] [Abstract][Full Text] [Related]
13. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
de Perrot M; Feld R; Cho BC; Bezjak A; Anraku M; Burkes R; Roberts H; Tsao MS; Leighl N; Keshavjee S; Johnston MR
J Clin Oncol; 2009 Mar; 27(9):1413-8. PubMed ID: 19224855
[TBL] [Abstract][Full Text] [Related]
14. Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.
Maruyama R; Shoji F; Okamoto T; Miyamoto T; Miyake T; Nakamura T; Ikeda J; Aoki Y; Wataya H; Asoh H; Ichinose Y
Jpn J Clin Oncol; 2005 Aug; 35(8):433-8. PubMed ID: 16006571
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
Habib EE; Fahmy ES
Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
[TBL] [Abstract][Full Text] [Related]
16. [Case of malignant pleural mesothelioma with long-term disease control after 4 different lines of systemic chemotherapy and pleurodesis].
Tanaka A; Takahashi T
Nihon Kokyuki Gakkai Zasshi; 2009 May; 47(5):383-7. PubMed ID: 19514499
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
[TBL] [Abstract][Full Text] [Related]
18. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
Lee CW; Murray N; Anderson H; Rao SC; Bishop W
Lung Cancer; 2009 Jun; 64(3):308-13. PubMed ID: 19004520
[TBL] [Abstract][Full Text] [Related]
19. [Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].
Margery J; Rivière F; Planchard D; Le Floch H; Ferrand FR; Mairovitz A; Besse B; Vaylet F; Ruffié P
Rev Pneumol Clin; 2010 Sep; 66(4):255-9. PubMed ID: 20933167
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.
Fennell DA; C Steele JP; Shamash J; Sheaff MT; Evans MT; Goonewardene TI; Nystrom ML; Gower NH; Rudd RM
Lung Cancer; 2005 Feb; 47(2):277-81. PubMed ID: 15639727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
